据Amber Tong报道，诺华公司（Novartis AG）将从中国的艾博生物（Abogen Biosciences）获得一种基于信使RNA（mRNA）的自身免疫疗法的许可，交易总额高达78亿美元。
By Amber Tong Novartis AG will license a messenger RNA-based autoimmune therapy from China’s Abogen Biosciences, in a deal worth as much as $7.8 billion.
艾博生物周五在一份声明中表示，这家瑞士制药商将支付5.75亿美元的首付款，以获得一种mRNA编码的T细胞衔接器的权利，该药物能促使患者自身产生治疗分子。
The Swiss drugmaker will pay $575 million upfront for rights to an mRNA-encoded T-cell engager that makes the patient’s body produce the therapeutic molecule, Abogen said in a statement Friday.
艾博生物的药物ABO2203旨在通过耗竭导致自身免疫疾病的白细胞来重置免疫系统。该协议还涵盖了艾博生物RNA平台其他潜在项目的选择权。跨国制药商持续对中国药物表现出浓厚兴趣以充实其研发管线。
Abogen’s drug, ABO2203, is designed to reset the immune system by depleting a type of white blood cell that drives autoimmune diseases — conditions in which the immune system mistakenly attacks healthy organs and tissues. The agreement covers options for other potential programs from Abogen’s RNA platform. Multinational drugmakers have continued to show interest in Chinese drugs to fill their pipelines.
诺和诺德本周以26亿美元收购了江苏恒瑞医药开发的一种早期肥胖症口服药的权利，阿斯利康则投资20亿美元与Summit Therapeutics合作开发源自康方生物的癌症药物。
Novo Nordisk A/S this week acquired rights to an early-stage obesity pill developed by Jiangsu Hengrui Pharmaceutical Co. in a $2.6 billion deal and AstraZeneca Plc invested $2 billion in Summit Therapeutics Inc. to co-develop a cancer medicine originating from Akeso Inc. That followed GSK Plc’s deal with Chimagen Biosciences for a blood-cancer drug.
此前，葛兰素史克也与嘉晨西海（Chimagen Biosciences）就一种血液癌症药物达成了协议。
If all options are exercised and milestones met in the latest deal, Abogen could receive up to $7.2 billion in additional payments.
如果所有选择权被行使且达到里程碑，艾博生物可能获得高达72亿美元的额外付款，并有资格获得未来产品销售的潜在特许权使用费。
Abogen may also be eligible to receive potential royalties on future product sales.
诺华此前曾测试过其他重置自身免疫的方法，包括细胞疗法，但在三名患者死亡后，近期已暂停了相关临床试验。
Novartis has tested other approaches to resetting autoimmunity, including with a cell therapy, but recently paused clinical trials after three patients died.